Good
Partially Aligned
Patient Risk:
Low
Summary
The evaluated response includes at least one mechanism-of-action claim that is supported by the provided FDA label excerpt (12.1). However, most other claims are outside the supplied label content (e.g., manufacturer/developer/history, approval timelines, patent status, and certain indications/uses), so they cannot be confirmed against the provided prescribing information.
Category Scores
Accurate Statements
Acalabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor.
Supported by FDA label excerpt section 12.1 (Mechanism of Action: 'Acalabrutinib is a small-molecule inhibitor of BTK...').
Acalabrutinib is a small-molecule inhibitor of BTK; it inhibits BTK enzymatic activity and leads to downstream inhibition of BTK-mediated signaling relevant to B-cell proliferation/trafficking and malignant B-cell proliferation/tumor growth (nonclinical).
Supported by FDA label excerpt section 12.1 (covalent bond with cysteine in BTK active site; inhibition of BTK enzymatic activity; effects on BCR/cytokine receptor pathway outputs; nonclinical inhibition of downstream signaling and malignant B-cell proliferation/tumor growth in mouse xenograft models).
Unsupported Statements
Acalabrutinib is manufactured by AbbVie Inc.
Manufacturer information is not present in the supplied FDA label excerpt.
Acalabrutinib was originally developed by Acerta Pharma.
Development/history attribution is not present in the supplied FDA label excerpt.
Acerta Pharma was acquired by AstraZeneca in 2016.
Company acquisition history is not present in the supplied FDA label excerpt.
AstraZeneca's subsidiary, Hematologics, advanced acalabrutinib.
Corporate/subsidiary advancement details are not present in the supplied FDA label excerpt.
Acalabrutinib is marketed as Calquence.
Branding/market name information is not present in the supplied FDA label excerpt.
Acalabrutinib is used to treat adults with mantle cell lymphoma (MCL).
Indications/usage text is not included in the provided label excerpt.
Acalabrutinib is used to treat adults with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Indications/usage text is not included in the provided label excerpt.
The FDA granted accelerated approval for acalabrutinib for MCL in October 2017.
Approval history/timing is not included in the provided label excerpt.
The FDA granted accelerated approval for acalabrutinib for CLL/SLL in March 2019.
Approval history/timing is not included in the provided label excerpt.
Information regarding the patent status and expiration dates for acalabrutinib can be found on DrugPatentWatch.com.
The label excerpt does not mention DrugPatentWatch.com or provide patent-status guidance.
Contradictions
Important Omissions
For indications (MCL and CLL/SLL), the provided evaluation does not include label-supported details such as the precise labeled indication language, any limitations (e.g., line of therapy), and key qualifying disease characteristics. These details are material for accurately matching FDA-approved indications.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-confirmed content provided is mechanistic (BTK inhibition) and does not directly describe dosing, contraindications, warnings, monitoring, or safety actions. Unsupported claims relate to product history/branding/approval timeline/patents/indications, which are not sufficient to establish safety implications from the provided excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most claims are not verifiable against the supplied FDA label content (only section 12.1 was provided). Indications, approval dates, and patent-resource statements are unsupported by the excerpt.
Suggested Improvement
Limit claims to those directly supported by provided label sections (e.g., 12.1 mechanism). For indications and approval history, use the exact FDA label wording from the relevant sections (e.g., INDICATIONS AND USAGE and any History of Changes/approval timeline sections) rather than external or uncited sources.